Positively Positive - Living with HIV/AIDS:
HIV/AIDS News
HIV and AIDS News from around the world
Worldwide 88.4 million people have been infected with HIV.
Worldwide 42.3 million people with HIV have died.
Practicing Safe Sex is our best resource in preventing HIV infection through sexual contact.
Sexual contact accounts for 95 percent of all new HIV infections worldwide.
Safe Sex = Disease Prevention – STAY SAFE!
Use A Condom Every Time!
“HIV needs to be in the media each and every day as most people only see snippets of news and these are not effective enough. For this reason, in 2007, I decided to include an HIV/AIDS News page where people could find information on many HIV (Human Immunodeficiency Virus) and AIDS (Acquired Immune Deficiency Syndrome) related issues, Infectious Disease,
and more.
I collaborate with individuals, groups, and organizations throughout the world, to include their HIV/AIDS news articles, press releases, events, workshops, conferences, and more on PositivelyPositive.ca. News items stay on the HIV/AIDS News page for a month,
and then News items go into the HIV/AIDS News Archives.”
Bradford McIntyre
Researchers Investigate Potential Treatment for Eliminating HIV from the Brain
December 20, 2024 • Research Highlight - National Institutes of Health - Despite decades of research and the availability of antiretroviral medications, HIV continues to pose a significant health challenge. While these medications can be used to eliminate the symptoms of HIV and prevent its spread to others, a cure has yet to be found.
One major challenge is that HIV can enter a dormant-like state, hiding in the body and evading treatments, only to reactivate later. HIV hiding in the brain is particularly difficult to access, as the blood-brain barrier—the protective membrane surrounding the brain—often prevents treatments from entering those tissues.
In a recent NIMH-funded study, researchers explored a potential solution by testing a drug called BLZ945 that targets a type of immune cell known as macrophages.
FACT SHEET: Update on the Biden-Harris Administration’s Commitment to Addressing the Global Mpox Outbreak
December 1, 2024 - The White House - For decades, the United States has been a leader in combatting infectious diseases. During the 2022 global outbreak of clade II mpox, the Biden-Harris Administration mounted a robust response by making vaccines, tests, and treatment available to those at risk in the United States and abroad. Now, the Democratic Republic of the Congo (DRC) is experiencing its largest mpox outbreak ever recorded, with more than 50,000 suspect cases in 2024. Multiple neighboring countries have confirmed their first ever mpox cases, and some are also experiencing widespread outbreaks. A handful of travel-related cases have also been recorded in countries outside the Africa region. As we face this outbreak in Central and Eastern Africa, the United States is again acting quickly to respond. At the UN General Assembly in September, President Biden announced that the United States is prepared to commit at least $500 million and to donate up to one million doses of mpox vaccines to support African countries in preventing and responding to this outbreak. We are delivering on that commitment, with two-thirds of our global mpox funding pledge fulfilled, and all of our pledged vaccine doses available now for countries that are ready to receive the doses.
The United States is also prepared to respond to clade I and clade II mpox cases domestically, with early detection and a robust testing landscape across the country, increased clinician education and community outreach, and widely available mpox vaccines in retail pharmacies and clinics. Travel-associated cases have been detected in Canada, Germany, India, Sweden, Thailand, and the United Kingdom. In November 2024, the United States also identified one case of clade Ib mpox in a California resident who had recently traveled to an affected country. No further domestic detections have occurred as of December 5, 2024, and the risk to the general public remains low.
Gilead Submits New Drug Application to U.S. Food and Drug Administration for Twice-Yearly Lenacapavir for HIV Prevention
Foster City, Calif., December 19, 2024 - Gilead- Lenacapavir Named 2024 “Breakthrough of the Year” by Science Magazine
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the company completed New Drug Application (NDA) submissions to the U.S. Food and Drug Administration (FDA) seeking approval of an investigational use of lenacapavir—the company’s twice-yearly injectable HIV-1 capsid inhibitor—for the prevention of HIV as pre-exposure prophylaxis (PrEP).
The submission is supported by data from the Phase 3 PURPOSE 1 and PURPOSE 2 trials conducted by Gilead. In the PURPOSE 1 trial (NCT04994509), data showed twice-yearly lenacapavir demonstrated zero infections in the lenacapavir group and 100% efficacy and superiority to background HIV incidence (bHIV) for the investigational use of HIV prevention in cisgender women. In the PURPOSE 2 trial (NCT04925752), there were two HIV infections in the lenacapavir group, demonstrating 99.9% of participants in the lenacapavir group did not acquire HIV infection and a 96% reduction in HIV infections compared to bHIV among a broad and geographically diverse range of cisgender men and gender-diverse people. In both trials, twice-yearly lenacapavir also demonstrated superiority of prevention of HIV infections when compared with once-daily oral Truvada® (emtricitabine 200mg and tenofovir disoproxil fumarate 300mg; F/TDF) and was generally well-tolerated, with no significant or new safety concerns identified. Based in part on these trial results, Science Magazine last week named lenacapavir its 2024 “Breakthrough of the Year”
New discovery by Case Western Reserve University School of Medicine researchers provides hope in fighting drug-resistant malaria
December 19, 2024 - by Case Western Reserve University - Malaria, caused by a parasite transmitted to humans through an infected mosquito’s bite, is a leading cause of illness and death worldwide.
Most susceptible are pregnant women, displaced people and children in developing countries, according to the U.S. Centers for Disease Control and Prevention.
Treating the disease is difficult because Plasmodium falciparum, the deadliest malaria parasite, is resistant to nearly all malaria medications.
But in a study published today in Science Advances, researchers at Case Western Reserve University describe how they may have found a new target: a cholesterol-managing protein called PfNCR1.
40 years later, the Pitt Men’s Study is still breaking ground in the fight against AIDS
December 19, 2024 - By Nichole Faina - Pittwire - University of Pittsburgh - In 1984, Charles Rinaldo launched a study to learn more about a mysterious illness befalling gay men across the U.S. He was 37 years old, only 6 years into his appointment as an assistant professor in the Pitt School of Medicine and School of Public Health, when he put the University on the map for groundbreaking AIDS research.
With the backing of a $4.2 million, four-year National Institutes of Health (NIH) contract, Rinaldo set out to recruit several thousands of gay men in the Pittsburgh tristate area to donate blood and other clinical specimens. It was the beginning of the Pitt Men’s Study, which aimed to uncover the process by which a virus leads to AIDS and the development of the disease post-diagnosis.
The Pitt Men’s Study recently commemorated 40 years of trailblazing research, including contributions to more than 1,700 scientific articles. The study is behind breakthroughs in understanding the transmission and treatment of HIV and AIDS and continues to impact the lives and careers of study participants and scientists alike.
Introducing POSITIVE DESTINATIONS – A video documentary
Dec 18, 2024 - HIV Justice Network - Positive Destinations is the new home for The Global Database on HIV-Specific Travel and Residence Restrictions (hivtravel.org), now hosted by the HIV Justice Network. The ability to travel, migrate, or relocate is an important part of life for many. For people living with HIV, however, this can come with added complexity. Some countries still impose restrictions on entry, stay, and residency based solely on HIV status, creating hurdles that can make travel difficult, stressful, or even impossible. Others limit access to HIV treatment for non-nationals creating additional barriers to travel, study, or relocate with HIV. Positive Destinations is here to help people living with HIV navigate these barriers with confidence and clarity. In this video we explain what Positive Destinations is and how the editorial team have worked on it to make it a valuable resource for people living with HIV and advocates alike.
Russia’s HIV Deaths Hit 30K Per Year, Undermining Dwindling Labor Force
December 17, 2024 - The Moscow Times - Around 30,000 Russians of working age die annually from HIV, according to Vadim Pokrovsky, the head of Russia’s Federal Methodological Center for HIV/AIDS Prevention.
This figure continues to rise alongside increasing treatment costs for the government and a lack of early HIV testing.
Read more...
AIDS Fund Philly shutting down at the end of 2024
December 17, 2024 - By Alexandra Simon - CBS News - After serving the Philadelphia community for more than three decades, AIDS Fund Philly announced that the nonprofit is shutting down at the end of this year.
In a Facebook post signed by the staff and board, AIDS Fund said it will conclude operations on Dec. 31, 2024.
Read more...
Global Fund, PEPFAR Announce Coordinated Effort to Reach 2 Million People with Lenacapavir for PrEP to Significantly Reduce Global HIV Infections
GENEVA | WASHINGTON D.C. - 17 December 2024 - Global Fund - The Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) and the United States President’s Emergency Plan for AIDS Relief (PEPFAR) have joined forces with the Children’s Investment Fund Foundation (CIFF) and the Bill & Melinda Gates Foundation (BMGF) to announce today a coordinated effort that will rapidly provide affordable and equitable access to twice-yearly injectable lenacapavir for HIV pre-exposure prophylaxis (PrEP) contingent upon regulatory approval from the U.S. Food and Drug Administration, relevant national pharmaceutical regulators, and a recommendation from the World Health Organization (WHO).
The Global Fund and PEPFAR are aiming to secure sustainable arrangements for countries to access this new, potentially game-changing HIV prevention innovation – backed by a significant commitment from CIFF, and with support from BMGF – that would enable access to lenacapavir for at least 2 million people over three years in countries supported by PEPFAR and the Global Fund.
Canadian researchers study frailty among aging people with HIV
December 17, 2024 - Canadian AIDS Treatment Information Exchange (CATIE) - In a study of older Canadians with HIV, 17% were considered frail – above the Canadian average
Frailty is an issue that increases with age and reduces a person’s ability to carry out everyday tasks and activities. Frailty can affect walking speed, ability to think clearly, muscle strength, and so on. In a study of people without HIV, researchers in Canada found that 8% of people over the age of 65 had some degree of frailty.
Another team of researchers in Canada, in cooperation with scientists who study aging in people with HIV in Italy, conducted a study of HIV-positive Canadians, all of whom were over the age of 65, to find out their degree of frailty. This study is called Change HIV.
Preparing the next generation of HIV/AIDS caregivers to end the epidemic prevention
December 16, 2024 - UIC today - University of Illinois Chicago - For nearly four decades, physicians and scientists have fought the HIV/AIDS epidemic. Due to their efforts, what was once a fatal diagnosis is now a manageable chronic disease for millions of people worldwide.
Since 1988, the University of Illinois Chicago has been on the front lines of this battle as home to the Midwest AIDS Training and Education Center. Based in the College of Medicine’s department of family and community medicine, the center has trained thousands of health care workers to treat people with HIV and AIDS and reduce new diagnoses.
Now, renewed funding from the federal Health Resources and Services Administration HIV/AIDS Bureau will help the center continue its critical work beyond its upcoming 40th anniversary.
Deadly mould strains highly likely to acquire resistance to new drugs
16 December 2024 - The University of Manchester - Scientists have identified strains of one of the world’s most dangerous fungal pathogens, already resistant to our most effective antifungal drugs, which are also 5-times more likely to acquire resistance to desperately needed new treatments in development.
The study – led by two University of Manchester researchers and published in Nature Communications – significantly advances our understanding of how Aspergillus fumigatus rapidly develops drug resistance.
The mould, found in soil, composts, and decaying vegetation, is potentially deadly to people with a range of health conditions including those with weakened immune systems and respiratory problems.
Millions of people develop invasive and chronic aspergillosis infections around the world every year, with mortality rates ranging between 30% to 90%.
Bloor-Yorkville event raises record $1.7 million for AIDS research
Dec. 14, 2024 - TORONTO STAR - The 28th annual Bloor Street Entertains fundraiser featured a performance by Crystal Waters.
Bloor Street Entertains was back in the heart of Bloor-Yorkville on Nov. 28 for a celebration of glamour and generosity in support of the Canadian Foundation for AIDS Research. The event — chaired by Candice Sinclair, Janice Fricker, Michael Liebrock and honourary chair Sylvia Mantella — brought out 1,000 attendees who raised a record $1.7 million for AIDS research. The night climaxed with an after-party headlined by Crystal Waters and featuring Canada’s own DJ Frank Walker.
Read more...
This is Saskatchewan | HIV rates in the province are the highest in Canada
Dec 14, 2024 - CBC News Saskatchewan - This is Saskatchewan podcast is looking into the province's record high HIV rates.
Host Leisha Grebinski talks with Dr. Cara Spence and Toby Esterby, chief operations officer of the Saskatoon Community Clinic.
IAVI and IPD sign agreement formalizing collaboration to advance vaccine development, manufacturing, and access in Africa
DAKAR, SENEGAL — December 13, 2024 - IAVI - The two partners will harness their complementary strengths to advance their shared mission of creating an innovative, end-to-end model for sustainable vaccine access in Africa
IAVI, a nonprofit scientific research organization dedicated to addressing urgent global health challenges including HIV, tuberculosis, and emerging infectious diseases (EIDs), and the Institut Pasteur de Dakar (IPD), a non-profit foundation focused on equitable, sustainable, and affordable access to health in Senegal, Africa, and worldwide, have signed an agreement to formally collaborate for vaccine development, manufacturing, and access in Africa. Leaders from the organizations met in Dakar to sign the agreement at the week-long celebration of IPD’s 100-year anniversary.
With the signing of this agreement, IAVI and IPD are establishing a collaboration to research, develop, manufacture, and commercialize a range of novel vaccine candidates for both endemic and emerging infectious disease (EID) threats – all manufactured using a common vaccine production platform.
World AIDS Day recognized in Stratford
December 13, 2024 - By Connor Luczka - Penticton Herald - Since 1991, the red ribbon has been an international symbol for AIDS awareness. Since 2012, local Stratford knitters have done their part to spread that very same symbol across the Festival City each year.
In honour of World AIDS Day on Dec. 1, 80 handknitted scarves were scattered around downtown Stratford to raise awareness for the Regional HIV/AIDS Connection (RHAC), a London based charity dedicated to positively impacting the lives of individuals and diverse communities living with, at risk for and affected by HIV/AIDS and hepatitis C.
Read more...
Health advocates are raising awareness about HIV & AIDS
December 13, 2024 - By Adrian Andrews - WFSU - HIV and AIDS awareness month is celebrated in December, with World AIDS Day on December 1.
December is HIV/AIDS Awareness Month, and health advocates across the state and country, are educating the public on the various treatment and prevention options for patients.
Florida is home to roughly 22 million people, and according to the Florida Department of Health (FDOH) and the Center for Disease Control (CDC), more than 128,000 Floridians are HIV positive—that’s the highest of any state in the U.S.
Read more...
HIV Drug Based in Research by Sundquist Lab is Science’s 2024 Breakthrough of the Year
12-Dec-2024 - by University of Utah Health - Wesley Sundquist, PhD, Samuels Professor and chair of biochemistry at the University of Utah, laid the foundation for the development of a highly effective, long-lasting prophylactic against HIV, which has been named the Breakthrough of the Year by Science, a top scientific journal. The drug lenacapavir, developed by Gilead Sciences, provides protection for half a year instead of one day and has performed extremely well in clinical trials.
Sundquist’s research focuses on understanding how the HIV virus is built on a molecular level and how it interacts with the body to infect and spread through cells.
By purifying and analyzing the protein shell that surrounds the virus’s genetic material, Sundquist’s team discovered what the shell looks like and how it’s put together. Importantly, the research team found that the virus’s shell is highly sensitive to changes. Making even small tweaks to the proteins that make up the shell stopped the virus from replicating as quickly, which suggested that drugs that affect the protein shell could prove to be effective.
25 years of HIV/AIDS research and activism
12 December 2024 - Story Nicole Forrest - UCT News - University of Cape Town - The University of Cape Town (UCT) has made inimitable contributions to the fight against the HIV/AIDS epidemic. At the forefront of its efforts has been the Centre for Integrated Data and Epidemiological Research (CIDER). On 5 December, UCT colleagues, as well as representatives from the health services, non-profit organisations and various research groups gathered to reflect on and celebrate the centre’s achievements. People with HIV, even those on effective treatment, are more vulnerable to cerebral small vessel disease (CSVD), especially as they age. This disorder can cause strokes, memory problems, and other cognitive difficulties.
At the beginning of the HIV/AIDS epidemic in the 1980s, HIV was spreading and developing into AIDS at such a rapid rate that it was predicted to become the cause of more deaths than any other disease in history.
Over the past 25 years, however, the world has seen a steady decline in new incidences of HIV infections and deaths from AIDs-related illnesses. Between 1995 and 2023, the world saw a 61% reduction in the number of new HIV infections worldwide, while deaths decreased by 70% between 2004 and 2023.
NIH research reveals new insights about how 'bad' cholesterol works in the body
December 11, 2024 - National Institutes of Health (NIH) - Findings could pave the way for more personalized treatments for cardiovascular disease.
National Institute of Health (NIH) scientists have made a significant breakthrough in understanding how "bad" cholesterol, known as low-density lipoprotein-cholesterol or LDL-C, builds up in the body. The researchers were able to show for the first time how the main structural protein of LDL binds to its receptor – a process that starts the clearing of LDL from the blood – and what happens when that process gets impaired.
The findings, published in Nature, further the understanding of how LDL contributes to heart disease, the world’s leading cause of death, and could open the door to personalizing LDL-lowering treatments like statins to make them even more effective.
Analysis Reveals an Additional Mechanism Behind Statin Therapy’s Heart-Related Benefits in People with HIV
December 11, 2024 - Mass General Brigham - Investigators who previously found that a daily statin pill helps prevent heart attacks and strokes in people with HIV have now discovered a potential mechanism that may help to stabilize plaques and prevent their rupture in blood vessels. The research, led by a team from Mass General Brigham, is published in JAMA Cardiology.
“Individuals with HIV tend to have an excess of noncalcified plaques that are vulnerable to rupture at a younger age, putting them at high risk for strokes, heart attacks, and sudden cardiac death,” said senior author Steven Grinspoon, MD, chief of the Metabolism Unit at Massachusetts General Hospital, a founding member of the Mass General Brigham health care system. “Understanding how statins benefit this population could lead to additional and more targeted therapies to protect their cardiovascular health.”
Over 1 in 5 adults worldwide has a genital herpes infection – WHO
11 December 2024 - World Health Organization (WHO) - Around 846 million people aged between 15 and 49 are living with genital herpes infections – more than 1 in 5 of this age-group globally – according to new estimates released today. At least 1 person each second – 42 million people annually – is estimated to acquire a new genital herpes infection.
Most of the time, these infections cause no or few symptoms. However, for some people they lead to painful genital sores and blisters that can recur throughout life, causing significant discomfort and often requiring multiple healthcare visits. According to the estimates, more than 200 million people aged 15 to 49 suffered at least one such symptomatic episode in 2020.
Updated Hep B Vaccine More Effective for People with HIV
December 11, 2024 - Weill Cornell Medicine - A newer vaccine against hepatitis B virus was clearly superior to an older vaccine type in inducing a protective antibody response among people living with HIV who didn’t respond to prior vaccination, according to the results of an international study led by a Weill Cornell Medicine investigator.
The study, reported Dec. 1 in JAMA, showed that hepatitis B vaccine with a cytosine phosphoguanine adjuvant, known as HepB-CpG, (trade name Heplisav-B) induced protective levels of antibodies in up to 99.4% of the subjects who received it. Such protection was seen in only 80.6% of subjects who received hepatitis B vaccine with an aluminum hydroxide adjuvant, known as HepB-alum, (trade name Engerix-B).
Understanding the Link Between HIV and Brain Health
December 11, 2024 - By Mark Michaud - University of Rochester Medical Center (URMC) - People with HIV, even those on effective treatment, are more vulnerable to cerebral small vessel disease (CSVD), especially as they age. This disorder can cause strokes, memory problems, and other cognitive difficulties.
New research supported by the National Institute of Neurological Disorders and Stroke and led by University of Rochester Medical Center (URMC) neurologist Giovanni Schifitto, MD, and cardiovascular biologist Jinjiang Pang, MD, PhD, will focus on Delta-like 4 protein (DII4) hypothesized to play a key role in the deterioration of the microscopic network of blood vessels that serve the brain.
UB team visits community health partners in Africa to develop drugs to fight HIV, TB
December 11, 2024 - By Laurie Kaiser - University at Buffalo - Faculty investigators from UB’s Center for Integrated Global Biomedical Sciences (CIGBS) recently traveled to Zimbabwe and South Africa to address two public health challenges devastating that part of the continent — the human immunodeficiency virus (HIV) and tuberculosis (TB).
Over 12 days, the four faculty members met with researchers at partner universities, and government and community programs, and conducted site visits of laboratories working to develop drugs to fight HIV and TB
Their visit comes at a time when millions are dying annually from the two health conditions.
“More than 420,000 individuals die each year of HIV-related illness in sub-Saharan Africa, and this represents a remarkable 65% of the global death total,” says Gene Morse, SUNY Distinguished Professor in the School of Pharmacy and Pharmaceutical Sciences.
Global leaders in the HIV response call for access to long-acting medicines
NAIROBI, 10 December 2024 - UNAIDS - Today, at the 55th Programme Coordinating Board for the Joint United Nations Programme on HIV/AIDS (UNAIDS), HIV leaders from across the world called for access to long-acting medicines for everyone who would benefit from them, to build toward a new era in the AIDS response.
Over the last two years, scientific breakthroughs have brought to the fore a new class of anti-HIV medicines with long-acting effects, allowing people at risk of HIV infection and those living with the virus to take medicines every few months. One is injected just twice a year. Recent studies have shown these medicines to be among the most effective ever developed. One study showed zero new infections among young African women using long-acting prevention drugs, while a study among key populations showed them more effective than oral medicines. Another study highlighted at the session showed encouraging results using long-acting HIV treatment in low- and middle-income countries.
At-home test kits for HIV, STIs aim to remove barriers for people in Waterloo region, Guelph and area
Dec 08, 2024 - Kitchener-Waterloo - Desmond Brown - CBC News - 'Accessible testing is a key step in preventing the spread of HIV and other STIs,' Dr. Matthew Tenenbaum says
People in Waterloo region, Guelph and Wellington County can now get a kit sent to their home to test for HIV and other sexually transmitted infections.
Patrick O'Byrne a professor at the University of Ottawa who is also a nurse practitioner and who developed the GetAKit program. He says they make it easier for people who may feel stigmatized or who may face barriers to getting tested.
Read more...
From Yemen to Mayotte, the spread of a highly drug-resistant cholera strain
2024.12.06 - INSTITUT PASTEUR - Scientists from the National Reference Center for Vibrios and Cholera at the Institut Pasteur, in collaboration with the Centre hospitalier de Mayotte, have revealed the spread of a highly drug-resistant cholera strain. The study was published on December 12, 2024 in the New England Journal of Medicine.
Cholera is an infectious diarrheal disease caused by certain bacteria of the species Vibrio cholerae. In its most severe forms, cholera is one of the most rapidly fatal infectious diseases: in the absence of treatment, patients can die within hours. Treatment primarily involves replacing lost water and electrolytes, but antibiotics are also used in addition to rehydration therapy. They are essential in reducing the duration of infection and breaking chains of transmission as quickly as possible.
A strain resistant to ten antibiotics – including azithromycin and ciprofloxacin, two of the three recommended for treating cholera – was identified for the first time in Yemen during the cholera outbreak in 2018-2019.
Ending HIV/AIDS stigma requires more effort
December 8, 2024 - JAMAICA OBSERVER - We can’t say we are surprised that there still exists in our country a degree of ignorance about HIV/AIDS. What we cannot accept, though, is the discrimination people living with the disease continue to face.
Still vivid in our memory is the story we published 14 years ago of a young woman who was subjected to the most humiliating and dehumanising existence before she died from complications associated with HIV/AIDS in July 2010.
Read more...
Mystery disease kills dozens in Congo – what we know so far
December 6, 2024 - The Conversation - A “mystery disease” recently struck the south-western corner of the Democratic Republic of Congo (DRC), killing between 67 and 143 people over two weeks. The disease was reported to cause flu-like symptoms of fever, headache, cough and anaemia.
An epidemiologist told Reuters that it was mainly women and children who were seriously affected by the disease. But little else is known about the disease so far.
Health officials in the DRC are urgently investigating this incident to identify the cause of this deadly outbreak. Initially, they would consider possible diseases known to be endemic to the region such as malaria, dengue or Chikungunya.
However, they are likely to face difficulties detecting the cause because of diagnostic testing infrastructure issues, as well as difficulties with sample collections, transport of those samples to laboratory and testing.
WHO announces the development of updated guidance on managing advanced HIV disease
6 December 2024 - World Health Organization (WHO) - WHO has made available the membership of the Guidelines Development Group (GDG) for the development of WHO updated Guidelines for managing advanced HIV disease.
The group will meet virtually from 14 – 16 January 2025 to review evidence on the use of CD4 testing for identification of advanced HIV disease; interventions for people with advanced HIV disease who are discharged from hospital following an illness, and preferred treatment regimen for the management of individuals with Kaposi Sarcoma. This guidance will focus on individual and public health benefits.
As HIV cases rise across Canada, the numbers have stabilized in northwestern Ontario — for now
Dec 06, 2024 - By Sarah Law - CBC News - Health-care workers credit harm reduction as key to preventing transmission
While there's been a 35 per cent jump in human immunodeficiency virus (HIV) cases across Canada, the numbers have stabilized in northwestern Ontario — and health-care workers largely attribute it to harm reduction services available in the region.
Read more...
Theatre Cares Vancouver comes to an end
December 4, 2024 - By Gail Johnson - Stir - The organization had been raising funds and awareness for those living with HIV/AIDS since 1991
Theatre Cares Vancouver was an artist-driven, volunteer-based organization that united the spirit of Vancouver’s performing-arts community with its supporters to raise funds and awareness for HIV/AIDS relief and other worthy causes.
The organization had been raising funds and awareness for those living with HIV/AIDS and for vulnerable members of the community since 1991. Theatre Cares Vancouver averaged, over 33 years, to raise $25,000 per year to distribute to worthy charities. That’s roughly $825,000 raised by volunteers.
Duke Team Identifies a Strategy to Guide the Immune System to Respond to HIV
December 03, 2024 - Duke Health - Highly specific HIV antibodies could be induced by vaccination using a new strategy developed by researchers at the Duke Human Vaccine Institute. Vaccination using this strategy may be able to counter the virus’s ability to outpace the immune system.
Publishing in Nature Communications, the researchers describe a strategy for engineering pieces of the HIV envelope that stimulate the immune system toward making protective antibodies.
“To achieve this, we have to find the right antibody and then guide it along the way toward key mutations that are really rare,” said senior author, Barton Haynes , M.D., director of the Duke Human Vaccine Institute. “What we have found is that the immune system does not want to make protective anti-HIV broadly neutralizing antibodies unless it receives some help. This study demonstrates that, with the help of computer simulations, we were able to find the right HIV envelope immunogens to guide the immune system to make the desired antibody types.”
How the speed of viral spread can be estimated by the analysis of genomic sequences
December 3, 2024 - Plos Biology - Evaluating the speed at which viruses spread and transmit across host populations is critical to mitigating disease outbreaks. A study published December 3rd in PLOS Biology by Simon Dellicour at the University of Brussels (ULB), Belgium, and colleagues evaluate the performance of statistics measuring how viruses move across space and time in infected populations.
Genomic sequencing allows epidemiologists to examine the evolutionary history of pathogenic outbreaks and track the spatial movement of an outbreak. However, the sampling intensity of genomic sequences can potentially impact the accuracy of dispersal insights gained through these evolutionary approaches. In order to assess the impact of the sampling size, researchers simulated the spread of several pathogens to evaluate three dispersal metrics estimated from the analysis of viral genomes: a lineage dispersal velocity (the speed at which lineages spread), a diffusion coefficient (how fast lineages invade space), and an isolation-by-distance signal (how genomic sequences of a population become less similar over geographic distance) metric.
UNAIDS appoints artist Funke Akindele as National Goodwill Ambassador for Nigeria
ABUJA, NIGERIA, 3 December 2024 - UNAIDS - The Joint United Nations Programme on HIV/AIDS (UNAIDS) is pleased to announce the appointment of Funke Akindele, a multiple award-winning actress, movie producer and director, as its new National Goodwill Ambassador (GWA) for Nigeria. This prestigious nomination recognizes Funke Akindele’s outstanding contributions to the fight against HIV and her unwavering commitment to advocacy, raising awareness, and driving efforts to end AIDS as a public health threat by 2030.
Funke Akindele’s career took off with her role in the United Nations Population Fund (UNFPA)-sponsored television series “I Need to Know”, which focused on adolescent reproductive health and rights, including HIV. Since then, she has captivated audiences worldwide, earning millions of fans and accolades for her unforgettable roles. Known as the “Queen of Box Office” in Nollywood, Funke holds the top three slots on the list of highest-grossing Nollywood films of all time, reflecting her prominence and influence in the industry.
Tracking down and eliminating HIV dormant in the body: a major step forward
2-Dec-2024 - by Universite de Montreal - Modern therapies help people living with HIV to survive, but scientists are still trying to decipher the deep mystery of how to eventually eradicate the virus for good. Now new laboratory work in Canada sheds light on the vulnerabilities of HIV's pockets of resistance in the body, and potential ways to thwart them.
Led by of Université de Montréal medical professor Éric Cohen, director of the human retrovirology unit at the UdeM-affiliated Montreal Clinical Research Institute, the work is published in the journal iScience.
The presence of cells containing latent forms of HIV, which are not sensitive to current antiretroviral treatments, is an obstacle to the eradication of HIV in people living with HIV. The elimination of these cells, known as reservoirs, would prevent the rebound of viremia observed in infected people who are on long-term treatment.
Remarks by President Biden, First Lady Jill Biden, Dr. Daniel Driffin, and Jeanne White-Ginder Commemorating World AIDS Day
December 2, 2024 - The White House - As a person living with HIV, working daily among the HIV Vira- — the HIV Vaccine Trials Network, days like World AIDS Day are significant to me.
For more than 36 years, nations near and far have raised awareness of those impacted by and living with HIV.
Today, with the theme of “Collective Action: Sustain and Accelerate HIV Progress,” I know we can continue to reduce the negative impact that HIV continues to have on our lives.
Action and progress link our globe as we continue to make advancements towards ending HIV. Action and progress have taken our world from no test for HIV to having rapid, home-based testing.
We went from medications that only stop HIV on one step of the life cycle to medications that stop HIV throughout the process of multiplying.
Biden displays AIDS Memorial Quilt at White House to observe World AIDS Day
Dec 1, 2024 -Associated Press - President Joe Biden had the AIDS Memorial Quilt spread on the White House South Lawn to observe World AIDS Day. Gathered with the president and his wife, Jill, were survivors, family members and advocates to memorialize the lives lost to the epidemic.
A Proclamation on World AIDS Day, 2024
December 1, 2024 - The White House - JOSEPH R. BIDEN JR - President of the United States of America - Our Nation has made enormous strides toward preventing, diagnosing, and treating HIV — a terrible disease that has stolen the precious lives of over 40 million people since the epidemic began in 1981. Despite our progress, over 39 million people worldwide continue to live with it, including over 1 million people in the United States. On World AIDS Day, we honor the memory of all those we tragically lost to HIV around the world. We stand in solidarity with all those who are courageously facing the disease today. And we renew our commitment to accelerating efforts to finally end the HIV/AIDS epidemic.
My Administration has made historic progress toward addressing this fight. In my first year in office, I reestablished the White House Office of National AIDS Policy and launched a new National HIV/AIDS Strategy, to put us on the path to end this epidemic by 2030. To that end, the Health Resources and Services Administration committed nearly $10 billion in funding through the Ryan White HIV/AIDS Program to ensure that low-income individuals in America with HIV can receive the medication and quality care they need. The Department of Health and Human Services is also working to guarantee that Americans have access to HIV interventions like pre-exposure prophylaxis (PrEP) and self-tests to prevent HIV. And the Centers for Medicare and Medicaid Services has ensured that PrEP medications — including long-term injectable options — and critical support services like counseling and screenings for HIV and hepatitis B are free for people with Medicare. Furthermore, the Centers for Disease Control and Prevention invested $10 million in a pilot program that covers the cost of PrEP to five health departments across the Nation — an important step toward ensuring everyone has access to this vital medication. Additionally, my Administration’s investments in the Ending the HIV Epidemic in the United States initiative, which reaches over 50 jurisdictions, has helped decrease HIV incidence by 21 percent in the past year in those areas.
Five things you should know about the HIV epidemic
December 1, 2024 - The Conversation - It is 40 years since Aids was first identified. Major strides have been made since the spread of the virus reached epidemic proportions in 1995 when 3.3 million people were infected with HIV and just under one million people died.
New HIV infections have reduced by 60% since the peak in 1995 and deaths are down by a third.
In 2023 1.3 million people became newly infected with HIV, while 630,000 people died from Aids-related illnesses.
Aids researchers Nomathemba Chandiwana and Linda-Gail Bekker outline the five key things we should know about HIV as we enter the second quarter of the 21st century.
Minister’s statement on World AIDS Day, Indigenous AIDS Awareness Week
Victoria - December 1, 2024 - BC Gov News - Government of British Columbia - Josie Osborne, Minister of Health, has issued the following statement in recognition of World AIDS Day and Indigenous AIDS Awareness Week:
“Dec. 1 marks World AIDS Day and the beginning of Indigenous AIDS Awareness Week. This is a time to renew our commitment to support and remove the barriers of stigma for people throughout the province who live with and are impacted by HIV/AIDS. This year’s theme, My Health, My Right!, represents the importance of making health care accessible and equitable to all.
“B.C. has been a global leader in the fight against HIV/AIDS since the 1980s, committing to providing resources people need, including education and treatment measures, in our steadfast commitment to ending the HIV/AIDS epidemic.
Statement from the Chief Public Health Officer of Canada on World AIDS Day
Ottawa, ON - December 1, 2024 - Public Health Agency of Canada - Today, marks World AIDS Day and the beginning of Indigenous AIDS Awareness Week. This year's theme, "Take the rights path," highlights the importance of safeguarding human rights as a cornerstone of protecting health. It calls on us to uphold dignity, equality, and compassion in our collective efforts to end the HIV epidemic. These core principles can help to reduce stigma and barriers to testing, treatment and care and guide Canada's actions to address sexually transmitted and blood-borne infections.
In 2023, there were 2,434 people newly diagnosed with HIV in Canada, which is a 35% increase since 2022. Individuals aged 25 to 39 made up a significant portion of the new cases. This upward trend in new HIV diagnoses is the result of many factors, including increased testing following decreased testing rates experienced during the pandemic. Social determinants of health and risk factors, such as housing insecurity, rural or remote residence, lower income, substance use, experiences of violence and lack of access to health care, also influence infection rates. The Public Health Agency of Canada continues to work with partners on equitable access to testing, treatment and care for HIV.
Global celebrities unite behind UNAIDS’ call for world leaders to “take the rights path to end AIDS”
GENEVA, 1 December 2024 - UNAIDS - This World AIDS Day (1 December), sixteen global celebrities, including Hollywood film star Luke Evans and singer-songwriter Sia of the Unstoppable hit song, are uniting behind UNAIDS’ call for world leaders to protect human rights, which they say is vital to ensuring the success of efforts to end AIDS.
The celebrities, including actress and comedian Margaret Cho; comedian and poet Alok Vaid-Menon; fashion designer and television personality Tan France; actor Alan Cumming; actor, broadcaster and comedian Stephen Fry; actress Uzo Aduba; Moroccan artist OUM; South African actress Thuso Mbedu; Chinese actor and singer Huang Xiaoming; professional football player Racheal Kundananji; Pakistani-British actor and comedian Mawaan Rizwan; Filipino model and actress Pia Wurtzbach; Ukrainian singer and TV show host Vera Brezhneva; and popular television presenter Erkin Ryzkullbekov have come together in support of UNAIDS call to “Take the rights path to end AIDS.”
Montreal researchers make breakthrough discovery in fighting HIV
Nov. 30, 2024 - By Jean-Benoit Legault - CTV News Montreal -Researchers in Montreal have made a breakthrough discovery in HIV research by finding a way to expel the virus from its hiding places and destroy it.
The elimination of these "reservoirs" is probably the last hurdle still to be overcome before we can hope to defeat the disease, but it's a major challenge, warned Professor Eric Cohen, whose team at the Montréal Clinical Research Institute (IRCM) is behind this breakthrough.
"This is the new frontier in HIV research," he said. "HIV is no longer a fatal disease, it's a chronic disease that can be managed with lifelong treatment, but the new frontier is really about finding ways of eradicating the infection, of curing [infected people] so that they no longer have to take medication."
Read more...
Media Release: World AIDS Day: Unite in the fight against HIV
Hastings and Prince Edward Counties - Nov. 29, 2024 - World Health Organization (WHO) - December 1 is World AIDS Day and the beginning of Indigenous AIDS Awareness Week. This day provides an opportunity for people worldwide to unite in the fight against human immunodeficiency virus (HIV), remember lives lost to HIV/AIDS and raise awareness of the actions individuals can take to protect themselves and others.
There’s more information available today than ever before, including ways to protect yourself and others. Unfortunately, despite these advancements, approximately four Canadians are infected with HIV every day; nearly one third of these are females.
On this World AIDS Day, Hastings Prince Edward Public Health (HPEPH) is reminding our community of the need to work together to raise awareness about HIV and AIDS.
Expert explainer: Why is a cure for HIV so elusive?
November 29, 2024 - By Cynthia Fazio - Western News - Western University - Schulich researchers share progress and challenges in ending the HIV epidemic
Schulich School of Medicine & Dentistry researchers are on the cutting-edge of the study of HIV, working toward treatments and a better understanding of how the virus works.
Finding a cure is no easy feat. But there is progress.
The theme for this year’s World AIDS Day on Dec. 1 is “Take the rights path: My health, my right!” In 2021, the Joint United Nations Programme on HIV/AIDS adopted a goal of ending human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) as public health concerns by 2030. To help achieve this goal, UNAIDS created the 95-95-95 targets, aiming for 95 per cent of people living with the virus to know their HIV status, 95 per cent of people who know their status to be receiving HIV treatment and 95 per cent of people on treatment to be virally suppressed.
FACT SHEET: The Biden-Harris Administration’s Efforts to End HIV/AIDS At Home and Abroad
November 29, 2024 - The White House - Ahead of World AIDS Day, we remember those who have died from AIDS-related illnesses—honoring their courage and contributions as essential to the progress made thus far. We also stand in solidarity with the more than 39 million people with HIV around the world. Four years ago, the Biden-Harris Administration renewed and strengthened the government’s bipartisan commitment to ending the HIV epidemic. Since then, significant progress has been made through a whole-of-society approach, unprecedented investments, and a steadfast commitment to leading with science, advancing equity, and addressing HIV stigma and discrimination.
WHO calls for action to fight growing HIV epidemic
Manila, Philippines - 29 November 2024 - World Health Organization (WHO) - HIV infections and AIDS-related deaths are on the rise in the WHO Western Pacific Region, reversing years of progress in the fight against the epidemic.
New HIV infections have risen by 8% and AIDS-related deaths by 10% since 2019, highlighting critical gaps in prevention, testing, treatment and care services, particularly for key populations, according to the World Health Organization (WHO)
HIV testing encouraged as World AIDS Day approaches
Nov 29, 2024 - SIMCOE MUSKOKA DISTRICT HEALTH UNIT - BRADFORD TODAY -The Ontario Advisory Committee on HIV/AIDS reports that 11 per cent of people living with HIV don’t know they have it
World AIDS Day is observed annually on Dec. 1 to raise awareness about human immunodeficiency virus (HIV) and the Simcoe Muskoka District Health Unit is reminding everyone that testing for HIV is important for protecting your health. This is because the Ontario Advisory Committee on HIV/AIDS reports that 11 percent of people living with HIV don’t know they have it. This means they will miss out on effective HIV treatment which protects their health, and they might unknowingly spread the virus to others.
Read more...
Ceremony held in Windsor for World Aids Day
Nov 29, 2024 - By Jean-Benoit Legault - CTV News Montreal - Researchers in Montreal have made a breakthrough discovery in HIV research by finding a way to expel the virus from its hiding places and destroy it.
The elimination of these "reservoirs" is probably the last hurdle still to be overcome before we can hope to defeat the disease, but it's a major challenge, warned Professor Eric Cohen, whose team at the Montréal Clinical Research Institute (IRCM) is behind this breakthrough.
"This is the new frontier in HIV research," he said. "HIV is no longer a fatal disease, it's a chronic disease that can be managed with lifelong treatment, but the new frontier is really about finding ways of eradicating the infection, of curing [infected people] so that they no longer have to take medication."
Read more...
Dr. Brian Conway: On this World AIDS Day, increase in new cases of HIV in B.C. must be taken as a cautionary tale
Nov 29, 2024 - By Dr. Brian Conway - VANCOUVER SUN - Opinion: B.C. has been a leader in this field, providing all treatments free of charge to those who need them. But the system not is not equally accessible to all
On this World AIDS Day 2024 (which we mark for the 37th time on Dec. 1), I am called to reflect on both our great progress over the past generation and what still lies ahead. I am truly concerned. In B.C. in the first half of 2024, there were 130 new diagnoses of HIV infection (five per week), compared to 98 in 2023 and 53 in 2022 over the same interval. This is still far lower than 10 per week experienced at the peak of the epidemic, but it is very worrisome and now appears to be a trend after the pandemic.
Read more...
How HIV Research Reshaped Modern Medicine
Newswise - 29-Nov-2024 - by Harvard Medical School - In 1981, fresh out of medical school, physician-scientist Bruce Walker began his internship at Massachusetts General Hospital. One day, a young patient showed up with an unusual cluster of infections and cancers. Baffled and powerless to treat him, Walker and his colleagues could only watch as the patient quickly succumbed to the mysterious condition.
“I distinctly remember the first case we saw at Mass General,” said Walker, who is the Phillip T. and Susan M. Ragon Professor of Medicine at Harvard Medical School and the director of the Ragon Institute of Mass General, MIT, and Harvard. “The attending physician said that although we didn’t know what this condition was, we probably would never see another case like it.”
Two weeks later, another patient came in with the same set of symptoms. It quickly became clear to Walker and his colleagues that they weren’t dealing with a rare disease — it was the beginning of a new epidemic.
World AIDS Day: Underdiagnosis and late HIV diagnoses are holding back progress to end AIDS in the European Region
Stockholm/Copenhagen - 28 November 2024 - European Centre for Disease Prevention and Control (ECDC) - Ahead of World AIDS Day, the new HIV/AIDS Surveillance Report 2024released by the WHO Regional Office for Europe and the European Centre for Disease Prevention and Control (ECDC), shows that since the beginning of the epidemic in the early 1980s, over 2.6 million people have been diagnosed with HIV in the WHO European Region, including more than 650, 000 in the European Union and European Economic Area (EU/EEA). Despite significant progress, nearly one in three people living with HIV in the WHO European Region are still unaware of their HIV status.
Academy Award-winning actress and philanthropist Charlize Theron hands over her Instagram account to 21-year-old HIV activist
GENEVA, 28 November 2024 - UNAIDS - A 21-year-old South African HIV activist, Ibanomonde Ngema, will take over the global Instagram account of Academy Award-winner and UN Messenger of Peace, Charlize Theron, on World AIDS Day (1 December) to bring awareness to the first-hand experiences of young people living with HIV. Nomonde, as her friends call her, was born with HIV and has dedicated her advocacy work to dispelling myths and reducing stigma around HIV.
Theron is a longstanding leader in advocating for young people and tackling the systemic inequalities that drive HIV infections among young women and girls, using her voice and platform to uplift the voices of youth alongside the work of her foundation in Southern Africa.
Clinical trial at Emory University reveals twice-yearly injection to be 99% effective in HIV prevention
Nov. 27, 2024 - Emory News Center - Emory University) - For oral medications that prevent new HIV infection to be effective, the patient must take certain actions, including attending doctor’s visits every three months and — most importantly — consistency.
These daily oral antiretrovirals, more commonly referred to as PrEP (pre-exposure prophylaxis), such as Truvada®, are extremely effective at HIV prevention, but only if they are taken daily as directed. Truvada’s efficacy is greatly compromised when taken inconsistently.
However, results from a recent Gilead-funded clinical trial (Purpose-2) led by physicians at Emory University and Grady Health System indicate that a twice-yearly injection of Lenacapavir offers a 96% reduced risk of infection overall, making the injection significantly more effective than the daily oral PrEP. The findings were recently published in the New England Journal of Medicine.
For People Living with HIV/AIDS, TB is Still the Leading Cause of Death
Newswise - NEW YORK, NY – Nov. 27, 2024 - by American Thoracic Society (ATS) - The latest World Health Organization’s Global Tuberculosis Report released in November 2024 painted a sobering picture; approximately 8.2 million people were newly diagnosed with TB in 2023, the highest number since the organization began global TB monitoring in 1995. TB is the leading cause of death among those with HIV /AIDS worldwide. According to the WHO, in 2023, 161,000 people died of HIV-associated TB.
This World AIDS Day, Dec. 1, the American Thoracic Society and our Forum of International Respiratory Societies (FIRS) partners call on governments, health advocates, and non-government organizations to strengthen their response to AIDS and TB. This collaborative effort is necessary to help realize the World Health Organization’s goal of ending the AIDS epidemic by 2030.
2024 WORLD AIDS DAY: Collective Action Needed to End HIV/AIDS, Common Ground for Divided Nation
Newswise — WASHINGTON, D.C.– 26-Nov-2024 - by Johns Hopkins School of Nursing - This World AIDS Day Sunday, December 1, the Center for Latino Adolescent and Family Health (CLAFH) along with the Institute for Policy Solutions (IPS) at Johns Hopkins School of Nursing is calling all sectors to act.
“Collective action on HIV/AIDS can be common ground for a divided nation. On World AIDS Day and beyond, please do something to end the epidemic once and for all. Please act collectively in your community and within your network. Reach out and practice the golden rule with compassion. Know that while you are helping speed the end of HIV/AIDS — you might be building bridges at a time our nation most needs them,” said Dr. Vincent Guilamo-Ramos, director of CLAFH and executive director of IPS.
U.S. Business Leaders Convene Ahead of World AIDS Day To Accelerate Efforts To End the HIV Epidemic
ATLANTA, Nov. 26, 2024 /PRNewswire/ - U.S. Business Action to End HIV - As the U.S. prepares to welcome a new presidential administration, leaders from business, public health, and community organizations gathered in Atlanta last week to reaffirm their dedication to ending the HIV epidemic and improving access to prevention and care.
The U.S. Business Action to End HIV coalition, launched by the Health Action Alliance (HAA) in December 2022, has grown into the nation's largest independent employer network dedicated to advancing workplace HIV education and expanding access to screening, prevention, and treatment services. Backed by founding partners Gilead Sciences, ViiV Healthcare, and other sponsors, the Coalition now represents a diverse and expanding community of over 100 businesses, including Chevron, CVS Health, KPMG, Match Group, Mercer, MISTR, One Medical, Paramount Pictures, SAP, Walgreens, Walmart, and Uber. HAA has also raised awareness of the Coalition within its network of more than 10,000 employers.
 
Canada’s longest-distance charity cycling event kicks off holiday fundraiser with $50K goal to support people living with HIV/AIDS during time of need
TORONTO, Nov. 26, 2024 (GLOBE NEWSWIRE) - Friends for Life Bike Rally - This Sunday, December 1, on World AIDS Day, and the start of Indigenous AIDS Awareness Week, the 27th annual Friends for Life Bike Rally launches its Holiday Season Fundraising Campaign. As local AIDS Service Organizations see a significant increase in demand for their life-changing services, the fundraiser aims to raise $50,000 in December – a month of generosity and giving from coast-to-coast-to-coast.
The Friends for Life Bike Rally is Canada’s longest-distance annual charity cycling event from Toronto to Montreal, raising funds for the Toronto People with AIDS Foundation (PWA), AIDS Community Care Montreal (ACCM) and Trellis HIV & Community Care (formerly HIV/AIDS Regional Services – Kingston) to support to those living with HIV/AIDS and fight stigma. The upcoming Friends for Life Bike Rally aims to raise a total of $1.8M by the end of its next charity ride that runs from August 3 to 8, 2025.
Biden-Harris Administration Policy Expands Access to Life-Saving Organs for People with HIV
November 26, 2024 - U.S. Department of Health & Human Services - Final Rule Removes Clinical Research Requirements for Kidney and Liver Transplants from Donors with HIV
Today, the U.S. Department of Health and Human Services (HHS) announced a final rule that will expand access to kidney and liver transplants for people with HIV by removing clinical research requirements for these transplants. This action marks a significant step forward in increasing the availability of life-saving organs for all patients regardless of their HIV status while continuing to reduce barriers and stigma for people with HIV.
The final rule, which further implements the HIV Organ Policy Equity (HOPE) Act, removes the clinical research and institutional review board (IRB) approval requirements for kidney and liver transplants between donors with HIV and recipients with HIV. This change is based on research demonstrating the safety and effectiveness of kidney and liver transplants between donors and recipients with HIV.
UNAIDS report shows that upholding human rights is vital for ending the AIDS pandemic
GENEVA, 26 November 2024 - UNAIDS - Ahead of World AIDS Day (1 December), a new report by UNAIDS shows that the world can meet the agreed goal of ending AIDS as a public health threat by 2030 – but only if leaders protect the human rights of everyone living with and at risk of HIV. The report’s message is summed up in its title: “Take the rights path to end AIDS”.
“Despite huge progress made in the HIV response, human rights violations are still preventing the world from ending AIDS,” said Winnie Byanyima, Executive Director of UNAIDS. “When girls are denied education; when there is impunity for gender-based violence; when people can be arrested for who they are, or who they love; when a visit to health services is dangerous for people because of the community they are from—the result is that people are blocked from being able to access HIV services that are essential to save their lives and to end the AIDS pandemic. To protect everyone’s health, we need to protect everyone’s rights.”
U.S. authorities warn about an emerging sexually transmitted fungus
November 26, 2024 - Canadian AIDS Treatment Information Exchange (CATIE) - A new sexually transmitted infection has been reported in the U.S., chiefly among men
This emerging fungal infection, called TMVII, can cause scaly lesions
The infection may be difficult to diagnose but responds to antifungal drugs
In 2023, doctors in Paris, France, reported on an emerging fungal infection called TMVII (trichophyton mentagrophytes genotype VII). Now in 2024, researchers in the United States have identified the same fungus-causing infections in four men. Researchers in New York City and with the U.S. Centers for Disease Control and Prevention (CDC) have stated that this fungus can cause itchy, ring-like “scaly lesions on the trunk, groin, genitals, or face […].” They add that the fungus causes symptoms that “might be mistaken for eczema, psoriasis or other dermatologic conditions; and frequently requires oral antifungal therapy.”
Expanding HPV vaccination to all adults aged 27-45 years unlikely to be cost-effective or efficient for HPV-related cancer prevention
25-Nov-2024 -American College of Physicians - A modeling study projected that HPV vaccination programs for adults aged 27 to 45 years could benefit subgroups at higher risk for HPV, but overall, the approach is more costly and less effective than vaccinating younger people. According to authors, this is the first study to examine the cost-effectiveness and HPV-related cancer prevention of vaccinating subgroups of adults in this age group at higher risk of HPV infection in the US. The findings are published in Annals of Internal Medicine.
KnowHIV, the future-forward Campaign to Raise Awareness of HIV in Ontario launches for World AIDS Day 2024
TORONTO, Nov. 25, 2024 /CNW/ - Ontario HIV Treatment Network - Using human-centered design across multiple touch points, the Ontario HIV Treatment Network is normalising a provincewide conversation about HIV, joining the global effort to end HIV transmission and ensure all people with HIV are diagnosed and have access to care and treatment by 2030
HIV is still a thing — and the Ontario HIV Treatment Network wants to say just that to Ontario residents. Launching in time for World AIDS Day on Dec 1, this simple message kicks off a multi-year provincial campaign to revive awareness and destigmatize HIV via a series of strategically designed billboards, posters and digital ads all supported by influencer marketing partnerships and both traditional and new media relations.
"We want people to know a lot has changed in HIV care since the epidemic of the eighties and nineties." says Martin McIntosh, Regional HIV/AIDS Connection executive director, an organization within a robust network of AIDS Service Organizations that connect Ontarians with access to treatment, testing and prevention services. "Today, with effective treatment, people living with HIV can lead long, healthy lives with no risk of passing HIV to their sexual partners. Still, many don't see themselves as at risk or face ongoing systemic and social barriers to care."
Sub-saharan Africa leads global HIV decline: Progress made but UNAIDS 2030 goals hang in balance, new IHME study finds
November 25, 2024 - Institute for Health Metrics and Evaluation (IHME) - University of Washington - Key takeaways:
In contrast, the percentage of the population without a suppressed level of HIV (PUV) increased by 116.1% in Central Europe, Eastern Europe, and Central Asia from 2003 to 2021.
The study authors are issuing recommendations to invigorate the global HIV response across global public health programs dedicated to HIV control and expansion of prevention services. The Institute for Health Metrics and Evaluation (IHME) has published a new study in The Lancet HIV journal that revealed significant progress in the global fight against HIV/AIDS, alongside a stark warning that current trends indicate the world is not on track to meet the ambitious UNAIDS 2030 targets.
The research, which analyzed the global, regional, and national burden of HIV/AIDS among 204 countries and territories from 1990 to 2021 and forecasted trends to 2050, highlighted a mixed landscape of achievements and challenges in the battle against this global epidemic.
Read Freddie Mercury’s Heartbreaking Announcement of His Diagnosis With HIV/AIDS, Released on This Date in 1991, Just a Day Before the Queen Frontman Died
November 23, 2024 - By Eli Wizevich - Smithsonian Magazine - Until Mercury released the statement, tabloid newspapers hounded the ailing singer, while only a smaller inner circle knew about the extent of his illness
As midnight reached West London and Friday night passed into the first minutes of Saturday, November 23, 1991, rock band Queen’s press officer released a statement on behalf of frontman Freddie Mercury.
“Following the enormous conjecture in the press over the last two weeks,” Mercury announced, “I wish to confirm that I have been tested HIV-positive and have AIDS.”
Read more...
Public Health Agency of Canada confirms the first case of clade I mpox in Canada
Ottawa - November 22, 2024 - Public Health Agency of Canada - On November 22, 2024, the Public Health Agency of Canada (PHAC) confirmed the first case of clade I mpox in Canada in an individual in Manitoba. This travel-related case is associated with an ongoing outbreak of clade I mpox in central and eastern Africa. The individual sought medical care for mpox symptoms in Canada shortly after their return and is currently isolating. A public health investigation, including contact tracing, is ongoing.
PHAC is working closely with public health authorities in Manitoba. The National Microbiology Laboratory (NML) notified the province on November 22 that the sample tested positive for mpox clade Ib. While clade II mpox has been circulating in Canada since 2022, this is the first case of clade I mpox confirmed in Canada.
The risk to the general population in Canada remains low at this time. PHAC continues to actively monitor the situation and will provide updated information as it becomes available.
HIV’s secret sweet tooth: T cell glycosylation determines variant entry
November 22, 2024 - National Heart, Lung and Blood Institute - Researchers share insight about strategies being studied to support the cardiovascular health of people living with HIV
When Tom Ortiz was diagnosed with HIV more than 30 years ago, he felt like he was handed a death sentence.
“In the early days, if AIDS didn’t kill you a heart attack would,” said Ortiz, a community health worker in Ohio. “It was either AIDS or a cardiovascular event.”
As a result, Ortiz got his affairs in order. “When I first acquired the disease, nobody made it very far,” he said. “A year [to live] was a long time.”
NHLBI honors World AIDS Day
November 22, 2024 - National Heart, Lung and Blood Institute - Researchers share insight about strategies being studied to support the cardiovascular health of people living with HIV
When Tom Ortiz was diagnosed with HIV more than 30 years ago, he felt like he was handed a death sentence.
“In the early days, if AIDS didn’t kill you a heart attack would,” said Ortiz, a community health worker in Ohio. “It was either AIDS or a cardiovascular event.”
As a result, Ortiz got his affairs in order. “When I first acquired the disease, nobody made it very far,” he said. “A year [to live] was a long time.”
Palm Springs City Council Approves Design for Palm Springs AIDS Memorial
PALM SPRINGS, CA (November 22, 2024) - Palm Springs AIDS Memorial Task Force - Palm Springs AIDS Memorial - Fundraising Continues in Order to Commence Engineering and Fabrication
The Palm Springs City Council voted 4-0 (with one council member absent) to accept the recommendation of the Palm Springs Public Arts Commission to approve the design and placement of the much-anticipated Palm Springs AIDS Memorial last night during a scheduled council meeting. The Council also approved allocating $65,000 to the Memorial to assist in the installation and increased the city's funding contribution to be a total of $125,000. The Council acted on a recommendation from the Public Arts Commission which earlier had accepted and approved the design of the Memorial and recommended to the Council that it also approve the design and designate funds for installation. The Memorial is a gift to the City by the Palm Springs AIDS Memorial Task Force and commemorates the many lives lost to AIDS while honoring the caregivers and survivors in the community. The idea of the Memorial has been in progress since 2012 and was designed pro bono by award-winning artist Phillip K. Smith III starting in 2020. In addition to the physical structure, an accompanying online component of the Memorial will be created and accessed via a QR code that will be prominently displayed within the Memorial site. This online experience is being conceptualized now, and details will be shared as it progresses. The goal is to unveil the Memorial in the Downtown Park along with the online experience between Fall 2025 and Spring 2026.
CARB-X Awards Additional Funding to Debiopharm for Continued Development of Early-Stage Antibiotic Targeting Drug-Resistant N. Gonorrhoeae Infections
Lausanne, Switzerland – Boston, USA -November 21, 2024 - Debiopharm - Debiopharm (www.debiopharm.com), a Swiss-based global biopharmaceutical company, is proud to announce the extension of funding from the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a global non-profit partnership dedicated to supporting early-stage antibacterial research and development to address the rising threat of drug-resistant bacteria. This funding will support the preclinical development of Debio 1453, a novel antibiotic specifically designed to combat Neisseria gonorrhoeae infections. In line with the Debiopharm’s vision to set a new standard for treating N. gonorrhoeae infections by developing antibiotics with targeted activity, while potentially avoiding microbiome dysbiosis, the newly awarded $5.76 million USD will facilitate the advancement of essential preclinical research, positioning Debio 1453 for clinical progression.
With Debio 1453, Debiopharm aims to provide a potentially valuable addition to the current antibiotic armamentarium, as a new treatment for N. gonorrhoeae infections, especially strains showing significant resistance to existing therapies. The project includes pivotal objectives such as the completion of non-clinical pharmacology and safety packages, the manufacturing of the active pharmaceutical ingredient (API) and drug product, and the submission for a first-in-human clinical trial.
B.C. teen avian flu patient still in critical condition; epidemiologist says risk to public low
November 21, 2024 - By Michelle Meiklejohn and Charles Brockman - CityNews Vancouver - The B.C. Ministry of Health says a teenager who was infected with H5N1, or avian flu, is still in critical condition after nearly two weeks.
On Saturday, Nov. 9, authorities shared that a teenager in the Fraser Health region had tested positive for the virus, otherwise known as bird flu.
Read more...
Virology experts gather at UMass Chan Medical School for 2024 MassCPR Symposium
November 20, 2024 - By Jim Fessenden - UMass Chan Medical School - More than a hundred infectious disease scientists, virologists, researchers, students and postdoctoral fellows representing 17 institutions from across the commonwealth converged on UMass Chan Medical School this week for the annual Massachusetts Consortium on Pathogen Readiness (MassCPR) Symposium.
Established in 2020 to enhance Massachusetts preparedness for future pandemics, MassCPR brings together hundreds of basic and translational scientists, clinicians and public health professionals from a variety of disciplines, including virology, immunology, microbiology, epidemiology, pathology, diagnostics and therapeutic development, computational biology, and clinical medicine. The focus of the 2024 symposium was the biology and infectious mechanisms of endemic, emerging and submerging viruses.
Billboards to end HIV-related stigma go on display
November 20, 2024 - Chloe Harcombe - BBC News, Bristol - A campaign has been launched to raise awareness of the stigma associated with HIV.
Six people have shared their experiences, which are displayed on digital billboards at bus stops in Bristol, North Somerset and South Gloucestershire, ahead of World Aids Day on 1 December.
Read more...
An innovative antibiotic for drug-resistant bacteria
November 20, 2024 - American Chemical Society (ACS) - Antibacterial drugs are important for treating infections. But increasingly, bacterial resistance to current drugs — so they don’t work well, or even at all — means new ones are urgently needed. Building on previous work, researchers in ACS Infectious Diseases have demonstrated a potential antibacterial treatment from a modified darobactin, a compound originally from a bacterium. The team reports proof-of-concept animal trials on infections caused by bacteria, including E. coli, that are known to develop drug resistance.
This study was published during the World Health Organization’s World Antimicrobial Resistance (AMR) Awareness Week from November 18 to 24.
ECDC OPENS ESCAIDE 2024 CONFERENCE
Stockholm, 20 November 2024 - European Centre for Disease Prevention and Control (ECDC) - The European Centre for Disease Prevention and Control (ECDC) is today opening the 2024 European Scientific Conference on Applied Infectious Disease Epidemiology (ESCAIDE), which is taking place from 20 - 22 November 2024 in Stockholm, Sweden, and has a special focus on the latest research concerning COVID-19, food-and waterborne diseases, HIV and sexually transmitted infections, vaccine-preventable diseases, influenza and respiratory viruses, antimicrobial resistance, and emerging diseases.
Plenary sessions feature internationally renowned speakers who will discuss a range of critical topics, including the balance of prevention versus cure with lessons drawn from cancer, crime, and climate change; insights on infectious diseases during times of conflict with a focus on Ukraine; and strategies for improving surveillance to better understand the spread of infectious diseases. Other discussions will cover preparedness for emerging threats under the concept of ‘Disease X’ and a fresh look at the future management of known diseases.
Andrew Sullivan survived the AIDS epidemic and then had to learn how to grieve
Nov 19, 2024 - CNN - Author Andrew Sullivan grew up in Britain seeing his mom struggle with mental illness. He came to America as a young gay man and was named editor of The New Republic magazine, just as his friends began dying around him. Anderson talks with Andrew about surviving the AIDS epidemic and the complicated grief he feels following his mother’s death several months ago.
FACT SHEET: Continuing a Legacy of Leadership at the G20
November 19, 2024 - The White House - From day one of his administration, President Biden pledged to restore U.S. leadership and strengthen our partnerships to make America more secure and prosperous. Taking office amid a devastating pandemic that had upended the global economy, President Biden recognized that we needed to work with partners to tackle big cross-border challenges.
President Biden’s leadership at the G20 has demonstrated the dividends that U.S. engagement yields for America and the world. Through the G20, the Biden-Harris Administration has delivered a landmark agreement to stop the race to the bottom in corporate taxation; launched a new fund to address pandemic threats; and helped unlock hundreds of billions of dollars of resources at the international financial institutions to advance development progress and tackle global challenges.
Community pharmacies could expand PrEP access to help prevent HIV
19 November 2024 - University of Bristol - Centre for Academic Primary Care - A new study has found that community pharmacies could play a significant role in expanding access to pre-exposure prophylaxis (PrEP), a highly effective pill for preventing HIV infection. The researchers found that pharmacies could provide a more convenient and discreet option for those who are underserved by the current model of PrEP delivery through sexual health clinics in England.
The stigma surrounding sexual health services and their potentially inconvenient locations prevent some people from accessing PrEP. These barriers may disproportionately affect women, people from global majority communities and transgender people who may be at risk of acquiring HIV but are less likely to access PrEP through sexual health clinics.
The study was carried out by researchers from the Centre for Academic Primary Care, National Institute for Health and Care Research Applied Research Collaboration West (NIHR ARC West) and the NIHR Health Protection Research Unit in Behavioural Science and Evaluation (HPRU) at the University of Bristol. It involved interviewing community pharmacists and members of key at-risk groups to identify the barriers and facilitators of community pharmacy PrEP delivery using the Capability, Opportunity, Motivation, Behaviour (COM-B) model.
Collaboration between The Wistar Institute and Cameroon Researchers Reveals HIV Latency Reversing Properties in African Plant
PHILADELPHIA — (November 19, 2024) — The Wistar Institute —A collaboration between The Wistar Institute and the University of Buea in Cameroon has uncovered the mechanisms for a medicinal plant with anti-HIV potential in Croton oligandrus Pierre & Hutch, a species of African tree that has been used in traditional healing in Cameroon to treat a variety of diseases and conditions including cancers and diabetes.
The research team — a collaboration between Fidele Ntie-Kang, Ph.D., an Associate Professor of Pharmaceutical Sciences at the University of Buea and the Director of the University of Buea Centre for Drug Discovery, and Ian Tietjen, Ph.D., Assistant Professor and Education Director of Global Studies & Partnerships at The Wistar Institute’s Hubert J.P. Schoemaker Education and Training Center — published their findings in the Journal of Experimental Pharmacology in their paper, “Croton oligandrus Pierre & Hutch (Euphorbiaceae) extracts and isolated compounds reverse HIV-1 latency.”
This research is one of several discoveries on African chemical compounds that came from the collaboration between Wistar and the University of Buea Centre for Drug Discovery, which began in 2021. In addition to helping to advance HIV cure research in Cameroon, this collaboration also provided an opportunity for lead author Chantal Emade Nkwelle to travel from Cameroon to work at Wistar for five months, learn many of Wistar’s laboratory techniques on HIV research, and transfer them back to the University of Buea.
Overcoming stigma and discrimination in pursuit of reducing antimicrobial resistance: a Swedish approach
18 November 2024 - World Health Organization (WHO) - “Stigma that evolves from a bacterial threat, often without symptoms, is difficult to understand. Poor or mixed information can lead to uncertainty for people when making contact with the health-care system and in their social life,” says Dr Gudrun Lindh, a retired infectious disease specialist, PhD and senior consultant from the Department of Infectious Diseases at the Karolinska University Hospital and Karolinska Institutet in Stockholm, Sweden. Dr Lindh’s passion for epidemiology led to her work addressing antimicrobial resistance (AMR), including the social and mental health impacts of methicillin-resistant Staphylococcus aureus (MRSA).
MRSA is a common type of Staphylococcus bacteria that can be resistant to several antibiotics. These bacteria spread in the community through contact with people infected with MRSA and their wounds, or through contact with contaminated materials. MRSA maintains its position in the WHO Bacterial Priority Pathogens List for high-priority pathogens. Anyone can become infected with MRSA or carry MRSA without showing any signs or symptoms. The risk for acquiring MRSA increases for people receiving medical care in hospitals or long-term care facilities.
Miller School Infectious Disease Specialists Highlight HIV Work at Peru Conference
November 18, 2024 - byJosh Baxt - University of Miami Miller School of Medicine - Infectious diseases experts Dr. Susanne Doblecki-Lewis and Dr. Laura Beauchamps speak about outreach efforts and emerging therapies to help at-risk populations.
University of Miami Miller School of Medicine infectious disease researchers recently presented at theHIV Research for Prevention conference, HIVR4 P2024, in Lima, Peru. Sponsored by the International AIDS Society (IAS), the meeting focused on emerging therapies and outreach techniques to help at-risk communities stay healthy.
UM has long been at the epicenter of the HIV epidemic, and Miller School researcher/clinicians presented on their efforts to reach underserved communities and get people access to pre-exposure prophylaxis (PrEP), which can prevent infection, and other HIV/AIDS drugs.
Recently, we chatted with Susanne Doblecki-Lewis, M.D., a professor of medicine, chief of the Division of Infectious Diseases and director of HIV prevention at the Miller School, and Laura Beauchamps, M.D., associate professor of clinical medicine in the Division of Infectious Diseases, who shared their experiences at the conference.
Reducing antimicrobial resistance: accelerated efforts are needed to meet the EU targets
Stockholm, 18 November, 2024 - European Centre for Disease Prevention and Control (ECDC) - Data published by ECDC in connection with European Antibiotic Awareness Day shows that, despite improvement in some areas, the EU is lapsing in progress towards its 2030 antimicrobial resistance (AMR) targets.
Between 2019 and 2023, antibiotic consumption in the EU increased by 1%, moving further away from the 2030 target of a 20% reduction recommended by the Council of the European Union[1]. Although during the same period there have been significant reductions in methicillin-resistant Staphylococcus aureus bloodstream infections, the situation in other critical areas, such as carbapenem-resistant Klebsiella pneumoniae bloodstream infections, has worsened, with an increase in incidence by almost 60% between 2019 and 2023. This represents a growing threat to patients in hospitals across the EU, particularly since very few therapeutic options remain available to treat patients infected with carbapenem-resistant K. pneumoniae.
Crunching HIV/AIDS data during a time of fear (and loathing)
18 November 2024 - by Chris Mahony - Bayes Business School - This year marks four decades since scientists developed an antibody test for HIV, the breakthrough coming a year after it had been confirmed as the virus that causes AIDS.
It was an important milestone – and not just for clinicians and policymakers. Professionals across a range of industries had been grappling with the potential impact of a devastating and highly infectious disease.
For Professor Steven Haberman, appointed a decade earlier to teach on the pioneering new BSc in Actuarial Science at what is now Bayes Business School, HIV/AIDS was a uniquely sombre and difficult challenge as he and other experts assessed the potential impact on the life insurance industry.
Hari AIDS Sedunia 2024 - Pesan Sekretaris-Jenderal, António Guterres
Nov 17, 2024 - UN in Indonesia - World AIDS Day | Hari AIDS Sedunia | 1 Desember 2024
Transkrip pesan dalam Bahasa Indonesia::
Mengakhiri AIDS sebagai ancaman kesehatan masyarakat pada tahun 2030 dapat dicapai.
Namun untuk mencapai tujuan ini diperlukan upaya untuk menghilangkan hambatan-hambatan yang menghalangi masyarakat untuk mendapatkan layanan-layanan penting.
Setiap 25 detik, satu orang di dunia tertular HIV.
Message's transcript in English::
Ending AIDS as a public health threat by 2030 is achievable.
But reaching this goal requires breaking down the barriers keeping people from vital services.
Every 25 seconds, someone in the world is infected with HIV.
HIV and STI international screening week starts Monday
Nov 17, 2024 - Katrine Desautel - CityNews Montreal - Access to screening for HIV and other sexually transmitted and blood-borne infections (STBBIs) is still difficult in Quebec and elsewhere in the world. International Screening Week, which starts on Monday, advocates better access and encourages people at risk to go and get tested.
The international campaign promotes screening for HIV, hepatitis and STIs, and reaches some 50 countries. It was launched in 2020 due to delays in the number of tests carried out worldwide during the COVID-19 epidemic.
Read more...
California confirms first clade I mpox case
November 16, 2024 - Centers for Disease Control and Prevention (CDC) - CDC to receive samples for additional viral characterization.
The California Department of Public Health confirmed, through laboratory testing, the first known case of clade I mpox in the United States. This case is related to an ongoing outbreak of clade I mpox in Central and Eastern Africa. The risk of clade I mpox to the public remains low, and there continue to be sporadic clade II mpox cases in the United States.
The case was diagnosed in a person who recently traveled from Eastern Africa. The individual was treated shortly after returning to the United States at a local medical facility and released. Since then, the person has isolated at home, is not on treatment specific for mpox, and symptoms are improving. Based on their travel history and symptoms, patient specimens were tested and confirmed for the presence of clade I monkeypox virus. Specimens are being sent to CDC for additional viral characterization. Additionally, CDC is working with the state to identify and follow up with potential contacts.
Amid record year for dengue infections, new study finds climate change responsible for 19% of today’s rising dengue burden
NEW ORLEANS (November 16, 2024) - American Society of Tropical Medicine & Hygiene - Second study reveals how one Brazilian city escaped a historic outbreak this year by deploying mosquitoes carrying the Wolbachia bacteria that interferes with dengue transmission
Climate change is having a massive global impact on dengue transmission, accounting for 19% of the current dengue burden, with a potential to spark an additional 40%-60% spike by 2050 — and by as much as 150%-200% in some areas — according to a new study presented today at the Annual Meeting of the American Society of Tropical Medicine and Hygiene (ASTMH).
The findings from researchers at Stanford and Harvard Universities offer the most definitive evidence to date that climate change is a big factor driving a global surge in the mosquito-borne disease. Countries in the Americas alone have recorded almost 12 million cases in 2024 compared to 4.6 million in 2023, and locally acquired infections have been reported in California and Florida. The study also carries warnings of even sharper increases to come.
Canadian Foundation for AIDS Research receives two World Record titles
Nov 16, 2024 - By Rachel Morgan - CityNews Ottawa - The Canadian Foundation for AIDS Research (CANFAR) and Gilead Sciences Canada were awarded two Guinness World record titles Nov. 13 for both the Most Awareness Ribbons Made in One Hour by a Team and the World’s Largest Ribbon Mosaic Made Entirely of Awareness Ribbons. The agencies set out to beat the World Records as part of their collective World AIDS Day campaign, bringing awareness to the rising number of AIDS cases in Canada.
AIDS is still a global pandemic. In 2023, 1.3 million new cases were reported in Canada, representing a 25 percent increase in new cases since 2022.
Read more...
Guelph woman geared up to restart charitable bike repair
Nov 15, 2024 - Shelby Knox - CityNews Ottawa - A Guelph woman will soon resume repairing bicycles at her home thanks to an outpouring of support from the community.
Mary Rife has been fixing and selling bikes out of her garage for the last 14 years. In 2024 alone, she said she sold 296 bikes and raised over $25,000. That money, she told CTV News, goes to the Stephen Lewis Foundation to help people in Africa living with HIV and AIDS.
Read more...
Risk to United States from clade I mpox outbreak in Central and Eastern Africa
November 15, 2024 - CDC - CDC assessed the risk to the United States posed by the clade I mpox outbreak in the Democratic Republic of the Congo and neighboring countries across several populations of interest.
The purpose of this assessment is to provide context about the ongoing outbreak of clade I mpox in DRC and in countries in Central and Eastern Africa, to inform U.S. preparedness efforts.
This assessment is an update to our August 30, 2024 risk assessment, incorporating new evidence and breaking out specific populations at risk. We note that the overall U.S. population includes the specific populations assessed, but we include specific populations separately because the clade I mpox outbreak in DRC and in countries in Central and Eastern Africa may pose higher risks to these populations. We chose these specific populations based on the most common mpox transmission routes for both the current clade I outbreak and the clade IIb outbreak that began in 2022.
Hong Kong Advisory Council on AIDS concerned with rising situation of late presenters
November 15, 2024 - GovHK - The Government of the Hong Kong Special Administrative Region - The following is issued on behalf of the Hong Kong Advisory Council on AIDS:
The Hong Kong Advisory Council on AIDS (ACA) convened a meeting today (November 15). The ACA members were briefed by the Department of Health (DH) on the latest situation of Human Immunodeficiency Virus (HIV) infection and recent trends in Hong Kong, particularly the rising proportion of late presenters among newly reported cases, and its impact on local HIV control efforts.
Late presenters refer to individuals whose CD4 cells (one kind of immune cell) are being attacked by the virus and have decreased to a very low level (CD4 count of less than 200 cells/mm3) at the time of HIV diagnosis. Late presentation indicates that these individuals were not diagnosed and put on treatment in a timely way at an earlier stage of infection, resulting in a weakened immune system. Late presentation can lead to an increased risk of opportunistic infections and malignancies, leading to a higher mortality rate. In addition, as a result of an unsuppressed viral load, late presenters contribute to an increased risk of HIV transmission in the community, impacting the overall effectiveness of HIV control efforts and posing a significant burden to the healthcare system.
Warning One Quarter of People Living with HIV Lack Access to Life-Saving Treatment, Secretary-General Observance Message Urges Rights-Based Approach to Ending AIDS
15 November 2024 - United Nations - Following is UN Secretary-General António Guterres’ message for World AIDS Day, observed on 1 December:
Ending AIDS as a public health threat by 2030 is achievable. But, reaching this goal requires breaking down the barriers keeping people from vital services.
Read more...
Students who use dating apps take more risks with their sexual health
November 14, 2024 - Frontiers - Researchers from the US looked for associations between the use of dating apps, sexual behavior, and a history of HIV/STIs among college students in North Texas. They showed that there was an association between risky sexual behavior and the use of dating apps. They propose that the two may be mutually reinforcing.
In May, the WHO raised the alarm over the rise in incidence of sexually transmitted illnesses (STIs) in many regions of the world, currently running at more than a million new cases per day. Among high-income countries, the US has one of the highest prevalences of STIs, and this problem is getting worse. For example, the incidence of chlamydia has more than doubled since 2000, while gonorrhea increased by 40% and syphilis by 400%. The highest prevalence is among young adults between 20 and 34 years of age.
Over roughly the same period, technology made it easier than ever to find sex partners: more than half of Americans under 30 report using dating apps. Such apps have existed for over 20 years but became mainstream around 2010. Now, a new study in Frontiers in Reproductive Health shows that these two modern phenomena may be linked.
Study uncovers first evidence of resistance to standard malaria treatment in African children with severe malaria
INDIANAPOLIS - November 14, 2024 - by Jackie Maupin - Indiana University - Researchers have uncovered evidence of partial resistance to artemisinin derivatives — the primary treatment for malaria — in young children with severe malaria.
Indiana University School of Medicine researchers, in collaboration with colleagues at Makerere University in Uganda, have uncovered evidence of partial resistance to artemisinin derivatives — the primary treatment for malaria — in young children with severe, or "complicated," malaria.
Earlier studies have shown partial resistance to artemisinin in children with uncomplicated malaria, but the new study, published in the Journal of the American Medical Association (JAMA), is the first to document such resistance in African children with well-defined signs of severe disease from malaria.
Indiana has six HIV criminalization laws. Most criminalize conduct that cannot transmit HIV
November 14, 2024 - The Williams Institute - Indiana has six laws that criminalize people living with HIV (PLWH), spanning both the public health and criminal codes. A new report by the Williams Institute at UCLA School of Law evaluates whether these laws reflect current understandings of HIV science and criminalize conduct that poses negligible or no risk of transmitting HIV.
Results show that most of Indiana’s HIV criminal laws have yet to account for decades of advances in HIV science, and none are currently written with enough specificity to prevent criminalizing behaviors that have little to no risk of transmitting HIV.
New roles in infectious process for molecule that inhibits flu
November 14, 2024 - Ohio State News - The Ohio State University - In study, lack of immune protein increases risk of infection by unfamiliar viruses
Researchers have identified new roles for a protein long known to protect against severe flu infection – among them, raising the minimum number of viral particles needed to cause sickness.
The protein also helps prevent unfamiliar viruses from mutating after they infect a new host, the study found – meaning its absence during an immune response could enable an animal virus spilled over to people to adapt rapidly to human hosts.
The combined findings by scientists at The Ohio State University add up to potential trouble for people deficient in the protein, called IFITM3 – especially if an avian or swine flu were to gain hold in humans and cause widespread disease.
HITN-TV Partners with South Florida PBS to Bring "From Fear to Hope: The HIV & AIDS Journey" to Hispanic Audiences Nationwide
November 14, 2024 - BROOKLYN, N.Y.--(BUSINESS WIRE)-- HITN - Documentary premieres in Spanish on HITN-TV in early 2025
HITN-TV, the nation's leading Spanish-language public broadcaster, is proud to announce a partnership with South Florida PBS to bring the documentary "From Fear to Hope: The HIV & AIDS Journey" in the Spanish language to Hispanic audiences nationwide.
The powerful documentary chronicles the decades-long fight against the HIV/AIDS epidemic. "From Fear to Hope" explores the personal stories, medical breakthroughs, and ongoing research that have shaped the journey, from the early days of crisis in the 1980s to the life-saving medical advancements that transformed HIV/AIDS into a treatable condition.
Today, there are over 1.2 million people living with HIV in the United States, including 316,900 who identify as Hispanic or Latino. Communities of color, including Hispanic and Latino populations, have been consistently impacted by the HIV/AIDS crisis at disproportionate rates. Despite Hispanic/Latino people making up only 19% of the total U.S. population, they accounted for 31% of new HIV diagnoses in 2022 and are estimated to represent 26% of people living with HIV nationwide.
In Memoriam: A. Cornelius Baker
November 14, 2024 - HIV.gov - This week, colleagues and friends worldwide mourn the passing of A. Cornelius Baker, a guiding light for the HIV, LGBTQ+, and global health communities—a champion for health equity who consistently led by example, inspiring those around him to strive for the highest ideals.
“It is hard to overstate the impact of his loss to the public health and HIV/AIDS communities or the place he held in my heart, personally,” said Kaye Hayes, MPA, Deputy Assistant Secretary for Infectious Disease and Director of the Office of Infectious Disease and HIV/AIDS Policy (OIDP).
People With HIV Are Uniquely Affected by Loneliness. Here Are Some Tips for Breaking the Cycle
Nov 14, 2024 - By Tim Murphy - TheBody - Evelynn Simaloi is lonely. Diagnosed with HIV in 1998 in her native Kenya, she moved in 2017 to Indianapolis, where she lives with her mother, brother, sister, and two kids. But despite having many family members around her, she longs for someone—a romantic partner or even a close friend—with whom she can really connect. “Just to be with someone whom you can relate to about grown-up things, walking together or going to a movie,” she said, is the kind of thing she yearns for.
Read more...
Vaccine shows promise in curing HIV, Hong Kong biotech start-up says
14 Nov, 2024 - Xinmei Shen - South China Morning Post - ‘We may be on the brink of a breakthrough,’ Dr Edward Leong, advisory board chairman of Immuno Cure says
A Hong Kong biotech company said its therapeutic HIV vaccine showed “promising” results in a recent clinical trial, taking it one step closer to offering patients an alternative to antiretroviral therapy, and eventually a functional cure for the virus that causes Aids.
Developed by Immuno Cure, based in Hong Kong Science Park, ICVAX demonstrated “exceptional safety and promising immunogenicity profiles” during its first-phase clinical trial carried out at the Shenzhen Third People’s Hospital, the company said. Forty-five people took part in the trial.
Read more...
Gilead Presents Full PURPOSE 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow
FOSTER CITY, Calif.--(BUSINESS WIRE)- November 13, 2024 - Gilead- – Newly Presented Results, to be Published in The New England Journal of Medicine, Include Adherence and Pharmacokinetics Data; Data Underscore High Efficacy and Safety Profile of Lenacapavir Among Broad and Geographically Diverse Range of Individuals –
– FDA Recently Granted Breakthrough Therapy Designation for Lenacapavir for PrEP; Gilead to Begin Regulatory Filings by End of 2024 –
– Gilead Spearheading Lenacapavir Access Strategies to Ensure Scientific Innovation
Translates to Global Access and Real-World Impact –
Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752), which is studying twice-yearly lenacapavir, the company’s injectable HIV-1 capsid inhibitor, for the investigational use of HIV prevention among a broad and geographically diverse range of cisgender men and gender-diverse people. Newly presented results include data on adherence to and pharmacokinetics of lenacapavir among trial participants.
The data were presented during an oral abstract session at the International Congress on Drug Therapy in HIV Infection (HIV Glasgow) and will be published in The New England Journal of Medicine . The release of the full PURPOSE 2 data follows the unblinding of the trial at interim analysis in September and a presentation of additional efficacy and safety data last month at the HIV Research for Prevention Conference in Lima, Peru. Those previously reported data showed that lenacapavir reduced HIV infections by 96% compared to background HIV incidence (bHIV), with two incident cases among 2,179 participants, corresponding to 99.9% of participants not acquiring HIV infection in the lenacapavir group. Twice-yearly lenacapavir also demonstrated superiority to once-daily Truvada ® (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg; F/TDF) for pre-exposure prophylaxis (PrEP) and was generally well-tolerated, with no significant or new safety concerns identified.
Key influenza-severity risk factor found hiding in plain sight on our antibodies
November 13, 2024 - By Bruce Goldman - Stanford Medicine - Why do some people develop severe flu symptoms? A Stanford Medicine study points the finger at an unsung portion of the antibodies our immune systems generate to fend off invading pathogens.
Viruses are the fastest-evolving biological entity on earth. This fact explains why we need flu shots every year: Seasonal influenza perennially outwits the immunity we’ve acquired from previous vaccinations or infections.
Some new strains are rougher than others. The 1918 flu pandemic killed 50 million people and infected one-fifth of the world’s population. Influenza pandemics also occurred in 1957, 1968 and 2009.
“Influenza remains an incredibly dangerous risk to global health,” said Taia Wang, MD, PhD, associate professor of infectious diseases and of microbiology and immunology.
Guest Opinion: AIDS orgs may not survive to see the end of the pandemic
November 13, 2024 - by Tyler TerMeer - Bay Area Reporter - We are extraordinarily fortunate in San Francisco to be making strides in ending the HIV epidemic that has ravaged our communities for over four decades. With every new annual HIV report from the San Francisco Department of Public Health, we let out a collective exhale as the number of new HIV diagnoses continues its downward trajectory. What an incredible victory for our community and what great promise the future holds.
But as we welcome this hopeful shift in the epidemic, I must urge you to remember: We are NOT there yet.
Read more...
1 Genomic Test Can Diagnose Nearly Any Infection
November 12, 2024 - By Levi Gadye - University of California, San Francisco - Next-generation metagenomic sequencing test developed at UCSF proves its effectiveness in quickly diagnosing almost any kind of pathogen.
A genomic test developed at UC San Francisco to rapidly detect almost any kind of pathogen – virus, bacteria, fungus or parasite – has proved successful after a decade of use.
The test has the potential to vastly improve care for neurological infections that cause diseases like meningitis and encephalitis, as well as speed up the detection of new viral pandemic threats. It uses a powerful genomic sequencing technique, called metagenomic next-generation sequencing (mNGS).
Rather than looking for one type of pathogen at a time, mNGS analyzes all the nucleic acids, RNA and DNA, that are present in a sample.
Sexually Transmitted Infections Surveillance, 2023
November 12, 2024 - CDC - Sexually Transmitted Infections Surveillance, 2023 provides the most current and complete data for three nationally notifiable STIs: chlamydia, gonorrhea, and syphilis, including congenital syphilis.
New study links historical redlining to delays in HIV treatment
November 11, 2024 - By Andrew Yawn - Tulane University - A new study from Tulane University finds that historical, race-based lending practices are still impacting health today, linking these discriminatory policies to delays in effective HIV treatment within affected neighborhoods.
The lending practice, called redlining, was abolished in 1968. Yet, those living in once historically redlined neighborhoods experience 15% longer delays in achieving viral suppression of HIV compared to those in non-redlined areas, according to the study published in JAMA Internal Medicine.
The disparity can impact both individual health outcomes and public health efforts to curb the spread of HIV, said senior author Scott Batey, PhD, professor at Tulane’s School of Social Work.
Surviving Together
November 11, 2024 - By Tim Murphy - POZ - Long-term survivors are advocating for those living with or at risk for HIV.
“This is not a nostalgia thing, all right?” says Cleve Jones of his latest HIV advocacy project. “It’s important for people to remember what happened, because someday there will be another pandemic.” In fact, notes Jones—one of the world’s best-known long-term HIV survivors largely due to his conceiving of the now iconic AIDS Memorial Quilt—it’s already happened: COVID-19.
Read more...
30 Years Since Pedro Zamora Passed to Spirit
November 11, 2024 - By Shawn Decker - POZ - Judd Winick shares his thoughts on Pedro, and how the real world around us all needs more of his departed friend’s unforgettable passion.
Thanks to the advent and access to HIV medication, I’ve had many years to share my admiration and gratitude for Pedro Zamora. Without his passion for education and willingness to go on MTV’s The Real World in 1994, the actual world would have been a whole lot more ignorant during a very scary time in the AIDS epidemic.
Today I woke to a post by Judd Winick, honoring his friend on the 30-day anniversary of his passing:
Read more...
The Positive Side, Fall 2024: Online launch
November 2024 - Canadian AIDS Treatment Information Exchange (CATIE) -
Date & Time:
Nov 21, 2024 1:00 pm ET
10:00 AM in Vancouver
You’re invited to celebrate the return of The Positive Side at an online launch for the Fall 2024 issue!
Since the previous issue in July 2022, CATIE received a grant to reimagine Canada’s health and wellness magazine for people living with HIV through a community-centred lens.
B.C. investigating 1st presumptive human avian flu case caught in Canada
Novembewr 9, 2024 - Shaurya Kshatri - CBC News - Teenager from Fraser Valley region in hospital as sample sent to lab for confirmation
British Columbia health officials are investigating what's believed to be the first human case of avian influenza caught in Canada after a teenager tested presumptively positive for the disease, the Ministry of Health announced Saturday.
Read more...
Positively RED Ball 2
November 9, 2024 - GHC’s HIV/AIDS Resource Program (HARP) - Sault Ste. Marie Museum - Are you ready for a fun and fabulous night out to support a great cause? Come to the RED Ball!
“Dare to walk the red carpet and make your entrance.”
For the second time, GHC’s HIV/AIDS Resource Program (HARP) has teamed up with The Sault Ste. Marie Museum to bring you The Positively RED Ball 2!
The Positively RED Ball 2 is a 19+ event organized to help raise funds to construct an HIV/AIDS Memorial Wall. This monument is to recognize those individuals who have passed or are living with / affected by HIV/AIDS here in Sault Ste. Marie.
Make your way to The Grand Gardens at 1324 Great Northern Road on Nov. 29, 2024, at 7:30 p.m., for an evening of HIV/AIDS education, food, entertainment, a 50/50 draw and more. Our Emcee Lana Von Archer will keep you entertained and DJ Matt J. Dub will have you dancing all night! Our Royal Guest of Honour, TICOT Queen Mum 2024-2025 Christine Decelles James, HIV advocate and speaker, will be attending from The Imperial Court of Toronto. Courtney from Indie Blue Photography will be on site taking gorgeous photos of the attendees.
Those attending are encouraged to be their most fabulous selves! Come dressed in your best RED attire.
Late-Breaking Clinical Data and Real-World Evidence Presented at HIV Glasgow as Gilead Extends Leadership Efforts Toward Ending the Epidemic
FOSTER CITY, Calif.--(BUSINESS WIRE)-- November 7, 2024 - Gilead - – Full Results From PURPOSE 2 Study Exploring Lenacapavir as a Potential Twice-Yearly HIV Prevention Option Among a Broad and Geographically Diverse Range of Cisgender Men and Gender-Diverse People –
– Four-Year Outcomes From Real-World BICSTaR Study Further Demonstrate the Consistent Efficacy and Safety Profile of Biktarvy, Providing Insights for HIV Clinical Care –
– Late-Breaking Oral Presentation From Phase 2 Study Evaluating an Investigational Once-Weekly Oral Combination Treatment Regimen of Islatravir/Lenacapavir –
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of HIV research findings at the International Congress on Drug Therapy in HIV Infection (HIV Glasgow 2024), taking place from November 10-13. The results from more than 40 studies across HIV treatment and prevention include late-breaking data and seven oral presentations. These findings reflect a robust portfolio and future-looking pipeline focused on person-centered drug development strategies to address unmet needs in HIV and help end the epidemic.
Get your red clothes out in support of the fight against HIV/AIDS
Nov 7, 2024 - By SooToday - Group Health Centre’s HIV and AIDS Resources Program (HARP) has once again teamed up with the Sault Ste. Marie Museum to present The Positively Red Ball 2 on Nov. 29 at The Grand Gardens
Get ready to dig your finest red clothing out of the closet for the second annual Positively Red Ball.
Group Health Centre’s HIV and AIDS Resources Program (HARP) has once again teamed up with the Sault Ste. Marie Museum to present The Positively Red Ball 2— a 19+ event aimed at raising awareness and funds in the fight against HIV/AIDS.
Read more...
Preventing HIV misdiagnosis: implementation guide
7 November 2024 - Technical document - World Health Organization (WHO) - HIV testing programmes need to ensure that all clients who test for HIV are provided with correct diagnoses. The accuracy of HIV testing is critical to prevent misdiagnosis, as the consequences of giving an incorrect test result can be serious for clients, HIV testing services, HIV programmes and public health.
A Gut Feeling About HIV and Heart Disease
Newswise -LOS ANGELES (Nov. 7, 2024) - by Cedars-Sinai - Q&A With Cedars-Sinai Researcher Ivan Vujkovic-Cvijin, PhD
Ivan Vujkovic-Cvijin, PhD, is a pioneer in the study of the gut microbiota and the surprising ways these microorganisms living in our digestive tracts affect our overall health. His discoveries have been featured in Nature, Science Translational Medicine, Cell Reports and other top scientific journals.
In his latest achievement, he landed a $2.7 million, five-year grant from the National Institutes of Health to investigate whether microbiota dysfunctions are contributing to the elevated risk of hypertension in HIV patients.
Adeeba Chairs Malaysian AIDS Foundation’s New Trustees Board
KUALA LUMPUR, Nov 6 - By CodeBlue - The Malaysian AIDS Foundation (MAF) is proud to announce the new line-up of its Board of Trustees for a two-year period, comprising a panel of nine members elected by the Malaysian AIDS Council, during its Annual General Meeting (Council Meeting) held on August 17, 2024.
David Warren, MD, to join UNMC as new infectious diseases chief
Nov 5, 2024 - Written by John Keenan - University of Nebraska Medical Center - Debra Romberger, MD, chair of the UNMC Department of Internal Medicine, has announced that David K. Warren, MD, will join UNMC as the chief of the division of infectious diseases on Jan. 13, 2025.
Dr. Warren, who also holds a master of public health degree, will succeed Mark Rupp, MD, who announced in 2023 that he would be stepping away from the position while remaining at UNMC and Nebraska Medicine in his faculty and clinical roles.
Stopping mpox: wild meat markets are a root cause and must be made safer
November 5, 2024 - The Conversation - In many countries around the world, wild animals are sometimes killed for food, including monkeys, rats and squirrels.
Wild meat makes significant contributions to nutrition in Africa and to satisfying food preferences in Asia.
In Africa, the annual harvest of wild meat, estimated at between 1 million and 5 million metric tonnes, is substantial compared to the continent’s livestock production of about 14 million metric tonnes per year.
Public health researchers have long highlighted unhygienic wild meat practices as potentially harmful due to the risk of pathogens jumping from animals to humans, especially through close contact during hunting, processing or consuming undercooked meat.
Department of Microbiology and Center for AIDS Research collaborate to host inaugural HIV Basic and Translational Research Symposium at UAB
November 04, 2023 - by Katherine Gaither - UAB | The University of Alabama at Birmingham - The UAB Department of Microbiology and the Center for AIDS Research (CFAR) hosted the inaugural HIV Basic and Translational Research Symposium Wednesday, Oct. 23, 2024, at the UAB Hilton Hotel. The all-day event featured speakers from the university and Southern Research, time for discussion, and a poster session.
The symposium sought to increase awareness of basic and translational research on HIV, related co-morbidities, and associated fundamental biology ongoing at UAB. In addition, the event intended to foster new collaborations and multi-disciplinary research while highlighting resources, funding opportunities, and services that can support HIV-related research at UAB.
Survey Finds Continued Declines in HIV Clinician Workforce
Newswise - November 4, 2024 - By Wolters Kluwer Health: Lippincott - Training and support needed to meet national Ending the HIV Epidemic goals, reports JANAC
The supply of healthcare professionals available to provide HIV care continues to decline, even as the need for HIV care and prevention is expected to increase, reports a survey study in the November/December issue of The Journal of the Association of Nurses in AIDS Care (JANAC). The official journal of the Association of Nurses in AIDS Care,JANAC is published in the Lippincott portfolio by Wolters Kluwer.
“Our study provides new insights into the numbers and characteristics of clinicians who will be available to provide HIV care in the coming years. This information will inform efforts to build the HIV workforce amid the ongoing shift from specialist care to primary care strategies,” comments Andrea Norberg, DNP, MS, RN, and John Nelson, PhD, CPNP, FAAN, of the Rutgers School of Nursing François-Xavier Bagnoud Center, Newark, NJ.
 
bioLytical Laboratories Inc. Announces Health Canada Authorization of its rapid INSTI® HCV Antibody Test for Professional Use in Canada
RICHMOND, British Columbia, Nov. 04, 2024 (GLOBE NEWSWIRE) -- bioLytical Laboratories Inc. - bioLytical Laboratories Inc. announced today the immediate availability of its INSTI® HCV Antibody Test in the Canadian market
bioLytical Laboratories Inc. ("bioLytical"), a global leader in rapid diagnostic tests, proudly announces that it has received Health Canada authorization for its INSTI® HCV Antibody Test for professional use in Canada. This allows the company to immediately enter the Canadian marketplace, offering healthcare professionals more options to screen their patients for hepatitis C quickly and accurately.
Hepatitis C is a liver infection caused by the hepatitis C virus (HCV). It is considered a sexually transmitted and blood-borne infection (STBBI) as it can be transmitted through sexual or blood contact and is spread primarily through blood. As a curable disease, regular access to rapid testing plays a crucial role in ending hepatitis C as a public health threat.
“We are thrilled to receive Health Canada authorization for our INSTI® HCV Antibody Test,” said Robert Mackie, CEO of bioLytical. “This approval underscores our dedication to bringing innovative, high-quality diagnostic tools to healthcare providers across Canada. With hepatitis C posing a significant public health challenge, our rapid test will help professionals diagnose more patients quickly and accurately, which is critical in the fight to eliminate hepatitis C in Canada.”
Ricky Martin Headlining AHF World AIDS Day Concert
MIAMI--(BUSINESS WIRE)--- November 01, 2024 - AIDS Healthcare Foundation (AHF) - Global icon to perform at Watsco Center in Coral Gables for annual commemorative event honoring those lost to HIV/AIDS, supporting those living with HIV/AIDS, and raising awareness
MIAMI--(BUSINESS WIRE)--Global superstar Ricky Martin will headline the annual World AIDS Day concert, presented by AIDS Healthcare Foundation (AHF), the world’s largest nonprofit HIV/AIDS service provider. The event takes place on Monday, December 2, 2024, at the Watsco Center at the University of Miami (UM) in Coral Gables, Florida. Complimentary tickets are available by registering at AHFevents.org.
World AIDS Day is commemorated each year on December 1st and is an opportunity for communities to unite in the fight against HIV, show support for people living with HIV, and remember those we’ve lost. The evening’s event also will feature a performance by renowned DJ and rapper DJ Spinderella, and the AHF Lifetime Achievement award will be presented to Dr. Julio Frenk, UM’s outgoing president and chancellor-designate for UCLA.
G20 commits to fighting the inequalities driving AIDS and other pandemics. Leaders back new initiative to widen production of medicines in every region
RIO DE JANEIRO, BRAZIL, 1 November 2024 - UNAIDS - Ministers at the G20 Ministerial in Rio De Janeiro have made new commitments to tackle AIDS and other pandemics, through addressing the inequalities driving them, both globally and nationally.
The commitments have been welcomed as a potential breakthrough against AIDS and other pandemics by international experts including Nobel Prize Winning Economist Joseph E. Stiglitz, world-leading epidemiologist Sir Michael Marmot, and former First Lady of Namibia Monica Geingos. The experts, who are the Co-Chairs of the Global Council on Inequality, AIDS, and Pandemics established by UNAIDS, have been in Brazil as part of the Council’s engagement of the G20.
For more HIV and AIDS News visit...
Positively Positive - Living with HIV/AIDS: HIV/AIDS News Archive
Back to Top
HIV/AIDS News
|
